Status:
NOT_YET_RECRUITING
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
Lead Sponsor:
MingSight Pharmaceuticals, Inc
Conditions:
CLL (Chronic Lymphocytic Leukemia)
SLL (Small Lymphocytic Lymphoma)
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eligibility Criteria
Inclusion
- Age 18 years or older.
- Diagnosis of CLL or SLL:
- History of histologically documented CLL or SLL that meets iwCLL diagnostic criteria according to the 2018 guidelines, and
- Indication for treatment as defined by the 2018 iwCLL guidelines, or the need for disease reduction prior to allogeneic transplantation.-
Exclusion
- Current transformation of CLL/SLL non-Hodgkin lymphoma or Hodgkin lymphoma.
- Active and uncontrolled autoimmune cytopenia(s).
Key Trial Info
Start Date :
July 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06979076
Start Date
July 1 2026
End Date
December 1 2028
Last Update
September 29 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.